| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Cell, Tumor, and Stem Cell Biology |
1 Reproductive Biology Unit and Division of Gynaecology Oncology, Department of Obstetrics and Gynaecology and Cellular and Molecular Medicine, University of Ottawa, Ottawa Health Research Institute, Ottawa, Ontario, Canada; 2 Diseases of Aging Program, Ottawa Health Research Institute, Ottawa, Ontario, Canada; and 3 Department of Pathology, State University of New York, Stony Brook, New York
Requests for reprints: Benjamin K. Tsang, Ottawa Health Research Institute, 725 Parkdale Avenue, Ottawa, Ontario, Canada K1Y 4E9. Phone: 613-798-5555, ext. 16040; Fax: 613-761-4403; E-mail: btsang{at}ohri.ca.
Akt is a determinant of cisplatin [cis-diammine-dichloroplatinum (CDDP)] resistance in ovarian cancer cells, and this may be related to the regulation of p53. Precisely how Akt facilitates CDDP resistance and interacts with p53 is unclear. Apoptotic stimuli induce second mitochondria-derived activator of caspase (Smac) release from mitochondria into the cytosol, where it attenuates inhibitor of apoptosis protein–mediated caspase inhibition. Whereas Smac release is regulated by p53 via the transactivation of proapoptotic Bcl-2 family members, it is unclear whether p53 also facilitates Smac release via its direct mitochondrial activity. Here we show that CDDP induces mitochondrial p53 accumulation, the mitochondrial release of Smac, cytochrome c, and HTR/Omi, and apoptosis in chemosensitive but not in resistant ovarian cancer cells. Smac release was p53 dependent and was required for CDDP-induced apoptosis. Mitochondrial p53 directly induced Smac release. Akt attenuated mitochondrial p53 accumulation and Smac/cytochrome c/Omi release and conferred resistance. Inhibition of Akt facilitated Smac release and sensitized chemoresistant cells to CDDP in a p53-dependent manner. These results suggest that Akt confers resistance, in part, by modulating the direction action of p53 on the caspase-dependent mitochondrial death pathway. Understanding the precise etiology of chemoresistance may improve treatment for ovarian cancer. (Cancer Res 2006; 66(6): 3126-36)
This article has been cited by other articles:
|
|
 |
|
  J.-P. Guo, S.-K. Shu, L. He, Y.-C. Lee, P. A. Kruk, S. Grenman, S. V. Nicosia, G. Mor, M. J. Schell, D. Coppola, et al. Deregulation of IKBKE Is Associated with Tumor Progression, Poor Prognosis, and Cisplatin Resistance in Ovarian Cancer Am. J. Pathol., July 1, 2009; 175(1): 324 - 333. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Chaudhry and E. Asselin Resistance to chemotherapy and hormone therapy in endometrial cancer Endocr. Relat. Cancer, June 1, 2009; 16(2): 363 - 380. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A.T. Hildebrandt, H. Yang, M.-C. Hung, J. G. Izzo, M. Huang, J. Lin, J. A. Ajani, and X. Wu Genetic Variations in the PI3K/PTEN/AKT/mTOR Pathway Are Associated With Clinical Outcomes in Esophageal Cancer Patients Treated With Chemoradiotherapy J. Clin. Oncol., February 20, 2009; 27(6): 857 - 871. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Lito, B. D. Mets, D. M. Appledorn, V. M. Maher, and J. J. McCormick Sprouty 2 Regulates DNA Damage-induced Apoptosis in Ras-transformed Human Fibroblasts J. Biol. Chem., January 9, 2009; 284(2): 848 - 854. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Jiang and Z. Dong Regulation and Pathological Role of p53 in Cisplatin Nephrotoxicity J. Pharmacol. Exp. Ther., November 1, 2008; 327(2): 300 - 307. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Cao, D. N. Petrusca, M. Satpathy, H. Nakshatri, I. Petrache, and D. Matei Tissue transglutaminase protects epithelial ovarian cancer cells from cisplatin-induced apoptosis by promoting cell survival signaling Carcinogenesis, October 1, 2008; 29(10): 1893 - 1900. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Selvendiran, L. Tong, S. Vishwanath, A. Bratasz, N. J. Trigg, V. K. Kutala, K. Hideg, and P. Kuppusamy EF24 Induces G2/M Arrest and Apoptosis in Cisplatin-resistant Human Ovarian Cancer Cells by Increasing PTEN Expression J. Biol. Chem., September 28, 2007; 282(39): 28609 - 28618. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L.-Z. Liu, X.-D. Zhou, G. Qian, X. Shi, J. Fang, and B.-H. Jiang AKT1 Amplification Regulates Cisplatin Resistance in Human Lung Cancer Cells through the Mammalian Target of Rapamycin/p70S6K1 Pathway Cancer Res., July 1, 2007; 67(13): 6325 - 6332. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Yang, M. Sun, X.-m. Sun, G. Z. Cheng, S. V. Nicosia, and J. Q. Cheng Akt Attenuation of the Serine Protease Activity of HtrA2/Omi through Phosphorylation of Serine 212 J. Biol. Chem., April 13, 2007; 282(15): 10981 - 10987. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
